Northwire Canada EditionSunday, October 18, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0% GOLD 4181.10 +0.3% SILVER 57.30 +0.3% COPPER 6.57 +0.3% OIL 99.02 +1.1% PALLADIUM 1118.60 −0.9% GBU 0.095 +0.0% ATY 0.225 +4.7% GRDM 0.215 +0.0% PPM 0.300 +0.0% GZD 0.040 −11.1% CAN 0.060 +0.0% BGF 0.025 +0.0% MSV 0.570 +0.0% CCMM 0.485 +0.0% MON 0.385 −6.1% OMI 0.245 −2.0% BUFF 0.800 +2.6% FEO 0.630 −3.1% LIB 0.710 −1.4% NPR 0.620 +0.0% QZM 0.380 +0.0%
Earnings

Bausch + Lomb Announces Third-Quarter 2025 Results

By The Northwire Desk — AI Analysis Oct 29, 2025 · 06:58 BLCO · 21.15 BAUSCH + LOMB CORPORATION
BLCO · Price

Executive Summary

  • Bausch + Lomb reported Q3 2025 revenue of $1.281 B, up 7% YoY (6% on a constant‑currency basis).
  • GAAP net loss widened to $(28) M versus a $4 M profit a year earlier, driven by higher income‑tax provision despite operating income growth.
  • Adjusted EBITDA (non‑GAAP) rose to $243 M, and adjusted EBITDA excluding acquired IPR&D increased to $243 M, reflecting strong operational performance across Vision Care, Surgical and Pharmaceuticals segments.

Key Details

  • Revenue by Segment (Q3 2025):
  • Vision Care: $736 M (+8% YoY, +6% cc) – growth from dry‑eye OTC portfolio, eye vitamins, SiHy Daily lenses & Biotrue® ONEday contacts.
  • Surgical: $215 M (+4% YoY, +1% cc) – driven by equipment sales and premium IOL implantables (enVista®, LUX).

  • Pharmaceuticals: $330 M (+8% YoY, +7% cc) – growth from MIEBO® dry‑eye product and International Pharma sales.

  • Operating Income: $95 M vs. $43 M in Q3 2024 (↑$52 M).

  • GAAP Net Loss: $(28) M vs. $4 M profit in Q3 2024; EPS (GAAP) = $(0.08) vs. $0.01 a year ago.

  • Adjusted Net Income (non‑GAAP): $66 M (↑$20 M YoY); Adjusted EPS = $0.18 vs. $0.13 prior year.

  • Cash Flow from Operations: $137 M, down $17 M YoY due to higher operating cash offset by transformation payments.

  • Balance Sheet Highlights: Cash & equivalents $332 M at Sept‑30 2025; diluted shares outstanding 357.4 M.

  • Full‑Year 2025 Guidance (updated):

  • Revenue: $5.050 B – $5.150 B (~5–7% constant‑currency growth).

  • Adjusted EBITDA excl. IPR&D: $860 M – $910 M (now narrowed to $870 M – $910 M).

  • R&D Progress: LUMIFY® Phase 3 met all endpoints; enrollment begun for bioactive lens, next‑gen lifitegrast, ocular surface pain and glaucoma studies.

  • Conference Call: Wednesday, Oct 29 2025 at 8:00 a.m. ET (webcast link provided).

Notable Quotes

“We’re delivering on the vision we laid out in 2023… our pipeline will be on full display in just a few weeks at investor day.” – Brent Saunders, Chairman & CEO

Read the original news release →

More from BAUSCH + LOMB CORPORATION

Jul 01, 2026 · 07:00

Dry Eye Survey Reinforces Premium Pricing Power, But Lacks Catalyst to Break Recent Consolidation

Other Jun 01, 2026 · 06:59

Bausch + Lomb Expands Dry Eye Portfolio with Preservative-Free Blink Launch; Execution on $7B Pipeline Continues Amid Margin Expansion

Financings May 19, 2026 · 07:00

Bausch + Lomb Executes H1 2026 Launch Plan Amidst Margin Expansion Push

Other May 07, 2026 · 07:00

Bausch + Lomb Expands Surgical Portfolio with European Bi-Blade+ Launch Amidst Guidance Raise

Other May 06, 2026 · 07:15

Bausch + Lomb Pipeline Webinar Confirms Long-Term Growth Narrative, But Near-Term Surgical Headwinds Persist Despite Q1 Guidance Raise

Other Apr 30, 2026 · 07:00

Bausch + Lomb Pipeline Validation Follows Q1 Guidance Raise Amidst Margin Expansion

Other